RegenxBio (RGNX) shares consolidating in a narrow bull flag around its 8-EMA after gapping higher on 9/13 after announcing a collaboration with AbbVie. A breakout above $44.50 in focus for a run back to recent highs and a measured target of $51.50. Shares are sitting just below resistance of a big multi-year range and a run above $50 has a target of $70 with the 2018 highs near $85.